SONOMA PHARMACEUTICALS INC(NASDAQ:SNOA) stock Fundamental Analysis

Fundamental Rating

Taking everything into account, SNOA scores 3 out of 10 in our fundamental rating. SNOA was compared to 194 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for SNOA as it has an excellent financial health rating, but there are worries on the profitability. SNOA is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year SNOA has reported negative net income.

In the past year SNOA had a positive cash flow from operations.

SNOA had negative earnings in each of the past 5 years.

SNOA had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The Return On Assets of SNOA (-27.42%) is comparable to the rest of the industry.

SNOA has a Return On Equity (-76.96%) which is in line with its industry peers.

		Industry Rank	Sector Rank
ROA	-27.42%
ROE	-76.96%
ROIC	N/A

ROA(3y)-30.51%

ROA(5y)-28.12%

ROE(3y)-67.28%

ROE(5y)-66.88%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 35.98%, SNOA is in line with its industry, outperforming 57.30% of the companies in the same industry.

SNOA's Gross Margin has declined in the last couple of years.

The Profit Margin and Operating Margin are not available for SNOA so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	35.98%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.79%

GM growth 5Y-4.46%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

SNOA does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for SNOA has been reduced compared to 1 year ago.

The number of shares outstanding for SNOA has been reduced compared to 5 years ago.

The debt/assets ratio for SNOA has been reduced compared to a year ago.

2.2 Solvency

SNOA has an Altman-Z score of -19.21. This is a bad value and indicates that SNOA is not financially healthy and even has some risk of bankruptcy.

SNOA has a Altman-Z score of -19.21. This is amonst the worse of the industry: SNOA underperforms 85.41% of its industry peers.

There is no outstanding debt for SNOA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	0
Altman-Z	-19.21

ROIC/WACCN/A

WACC9.68%

2.3 Liquidity

A Current Ratio of 3.34 indicates that SNOA has no problem at all paying its short term obligations.

The Current ratio of SNOA (3.34) is comparable to the rest of the industry.

A Quick Ratio of 2.49 indicates that SNOA has no problem at all paying its short term obligations.

SNOA has a Quick ratio of 2.49. This is comparable to the rest of the industry: SNOA outperforms 49.19% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	3.34
Quick Ratio	2.49

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

SNOA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -59.77%.

The Revenue has grown by 13.53% in the past year. This is quite good.

The Revenue has been decreasing by -7.66% on average over the past years.

EPS 1Y (TTM)-59.77%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%60.63%

Revenue 1Y (TTM)13.53%

Revenue growth 3Y-11.91%

Revenue growth 5Y-7.66%

Sales Q2Q%13.58%

3.2 Future

Based on estimates for the next years, SNOA will show a very negative growth in Earnings Per Share. The EPS will decrease by -41.70% on average per year.

The Revenue is expected to grow by 15.09% on average over the next years. This is quite good.

EPS Next Y24.72%

EPS Next 2Y-41.7%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year5.59%

Revenue Next 2Y15.09%

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SNOA. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SNOA. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

SNOA's Price/Free Cash Flow ratio is rather cheap when compared to the industry. SNOA is cheaper than 82.16% of the companies in the same industry.

		Industry Rank	Sector Rank
P/FCF	30.08
EV/EBITDA	N/A

4.3 Compensation for Growth

SNOA's earnings are expected to decrease with -41.70% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-41.7%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for SNOA!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

SONOMA PHARMACEUTICALS INC

NASDAQ:SNOA (2/21/2025, 8:00:02 PM)

After market: 2.4 +0 (+0.21%)

2.395

-0.02 (-1.03%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)02-05 2025-02-05/amc

Earnings (Next)06-16 2025-06-16/amc

Inst Owners1.26%

Inst Owner Change-99.74%

Ins Owners1.31%

Ins Owner Change0%

Market Cap3.88M

Analysts85.71

Price Target17.34 (624.01%)

Short Float %2.61%

Short Ratio0.3

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)26.32%

Min EPS beat(2)10.49%

Max EPS beat(2)42.16%

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)0

Avg Revenue beat(2)-12.89%

Min Revenue beat(2)-13.93%

Max Revenue beat(2)-11.85%

Revenue beat(4)0

Avg Revenue beat(4)-14.18%

Min Revenue beat(4)-15.63%

Max Revenue beat(4)-11.85%

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)-812.5%

EPS NY rev (1m)0%

EPS NY rev (3m)83.25%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)-8.63%

Revenue NY rev (1m)0%

Revenue NY rev (3m)-8.9%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.28
P/FCF	30.08
P/OCF	24.4
P/B	0.8
P/tB	0.8
EV/EBITDA	N/A

EPS(TTM)-3.96

EYN/A

EPS(NY)-1.82

Fwd EYN/A

FCF(TTM)0.08

FCFY3.32%

OCF(TTM)0.1

OCFY4.1%

SpS8.63

BVpS3.01

TBVpS3.01

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-27.42%
ROE	-76.96%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	35.98%
FCFM	0.92%

ROA(3y)-30.51%

ROA(5y)-28.12%

ROE(3y)-67.28%

ROE(5y)-66.88%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.79%

GM growth 5Y-4.46%

F-Score5

Asset Turnover1.02

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	0
Debt/EBITDA	N/A
Cap/Depr	20.27%
Cap/Sales	0.21%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	3.34
Quick Ratio	2.49
Altman-Z	-19.21

F-Score5

WACC9.68%

ROIC/WACCN/A

Cap/Depr(3y)97.01%

Cap/Depr(5y)87.41%

Cap/Sales(3y)1.09%

Cap/Sales(5y)1.08%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-59.77%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%60.63%

EPS Next Y24.72%

EPS Next 2Y-41.7%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)13.53%

Revenue growth 3Y-11.91%

Revenue growth 5Y-7.66%

Sales Q2Q%13.58%

Revenue Next Year5.59%

Revenue Next 2Y15.09%

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-7.75%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y102.46%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y103.11%

OCF growth 3YN/A

OCF growth 5YN/A

SONOMA PHARMACEUTICALS INC (SNOA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens